Compare 10X Genomics Inc (TXG) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs UBS Group AG Registered Ordinary Shares — how do they compare? 10X Genomics Inc trades at $78.6 (market cap $9.92B), while UBS Group AG Registered Ordinary Shares trades at $46.92 (market cap $144.63B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 14.6× 10X Genomics Inc's market cap, and UBS Group AG Registered Ordinary Shares pays a 2.32% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and UBS Group AG Registered Ordinary Shares for 0 Days on average.
| TXG | UBS | |
|---|---|---|
Market Cap | $9.92B | $144.63B |
Volume | 9,372,166 | 1,746,723 |
Sector | Health | Financials |
52-Week High | $97.74 | $55.72 |
52-Week Low | $11.48 | $36.41 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $9.44B | $311.50B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
